Browse News

Found 111 articles

• Apollo Medical Holdings, Inc. Schedules 2023 Second Quarter Financial Results Release and Conference Call

  7/28/2023

  Apollo Medical Holdings, Inc. announced that it will release financial results for the second quarter ended June 30, 2023, after the close of the stock market on Monday, August 7, 2023.

• Apollo Medical Holdings, Inc. Signs Definitive Agreement to Acquire Assets of Texas Independent Providers, Expanding Care Partners Business into Houston

  7/12/2023

  Apollo Medical Holdings, Inc. announced that it and its affiliated professional entity have entered into a definitive agreement to acquire assets relating to Texas Independent Providers, LLC.

• Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium

  4/11/2023

  Apollomics Inc. announced that the company’s Co-Founder and President, Sanjeev Redkar, MBA, Ph.D., will speak at the 23rd Annual R. Bryan Miller Symposium, an event exploring the interface of chemical biology and organic chemistry in honor of Professor R. Bryan Miller, at the University of California, Davis on April 14, 2023.

• Qiming Venture Partners Welcomes Apollomics' Successful IPO on Nasdaq

  3/31/2023

  On March 30, 2023, Apollomics Inc., an innovative biopharmaceutical company and portfolio company of Qiming Venture Partners, listed on Nasdaq through a SPAC merger with Maxpro Capital Acquisition Corp.

• Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq

  3/30/2023

  Apollomics Inc., a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced the completion of its business combination with Maxpro Capital Acquisition Corp.

• GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022

  3/29/2023

  GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2022.

• Apollo Medical Holdings, Inc. Reports Fourth Quarter and Year-End 2022 Results

  2/23/2023

  Apollo Medical Holdings, Inc. today announced its consolidated financial results for the fourth quarter and year ended December 31, 2022.

• Beyond Cancer® Appoints Gavin Choy, PharmD as Chief Operating Officer

  1/30/2023

  Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announced today the appointment of Gavin Choy, PharmD as Chief Operating Officer.

• Apollo Medical Holdings, Inc. Receives NCQA's HEDIS Health Plan Measure Certification for Measurement Year 2022

  11/17/2022

  Apollo Medical Holdings, Inc. announced that ApolloMed received certification from the National Committee for Quality Assurance for the Healthcare Effectiveness Data and Information Set, following the development of its new HEDIS engine that identifies HEDIS gaps in care.

• Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations

  11/15/2022

  Apollomics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to vebreltinib (APL-101) for the treatment of non-small cell lung cancer (NSCLC) with MET genomic tumor aberrations.

• Apollo Medical Holdings, Inc. to Participate in Upcoming Virtual Investor Conferences

  9/21/2022

  Apollo Medical Holdings, Inc. today announced that management will be presenting at the following virtual investor conferences.

• Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.

  9/14/2022

  Apollomics Inc., a late-stage clinical biopharmaceutical company, and Maxpro Capital Acquisition Corp. announced a definitive agreement for a business combination that would result in Apollomics becoming a publicly traded company on the Nasdaq Global Market.

• Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer

  7/26/2022

  Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer.

• Apollo Medical Holdings, Inc. Schedules 2022 Second Quarter Financial Results Release and Conference Call

  7/21/2022

  Apollo Medical Holdings, Inc. today announced that it will release financial results for the second quarter and six months ended June 30, 2022, after the close of the stock market on Thursday, August 4, 2022.

• Laekna Therapeutics Raises $61 Million in Series D financing

  5/18/2022

  Laekna Therapeutics (" Laekna "), a clinical-stage global biotechnology company dedicated to developing next generation medicines to treat cancer and liver diseases, announced that it has raised $61 million in Series D financing led by CS Capital with support from Worldstar, and Infinity Capital.

• GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022

  4/28/2022

  GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the first quarter ended March 31, 2022. Cash and cash equivalents at March 31, 2022 were $76.5 million.

• Apollo Medical Holdings, Inc. Schedules 2022 First Quarter Financial Results Release and Conference Call

  4/28/2022

  Apollo Medical Holdings, Inc. announced that it will release financial results for the first quarter ended March 31, 2022, after the close of the stock market on Thursday, May 5, 2022.

• Tessa Therapeutics Appoints Wilson W. Cheung as Chief Financial Officer

  4/4/2022

  Tessa Therapeutics Ltd., a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced the appointment of Wilson W. Cheung as its chief financial officer effective April 1, 2022.

• GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2021

  3/3/2022

  GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the fourth quarter and year ended December 31, 2021. Cash and cash equivalents at December 31, 2021 were $90.3 million.

• Apollo Medical Holdings, Inc. Reports Fourth Quarter and Year-End 2021 Results

  2/24/2022

  Apollo Medical Holdings, Inc. announced its consolidated financial results for the fourth quarter and year ended December 31, 2021.